View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
Sponsored by Oncology Therapeutic Development (OTD)

Phase I Study: Bromodomain Inhibitor OTX015 in Patients with Acute Leukaemia

Free White Paper

Phase I Study: Bromodomain Inhibitor OTX015 in Patients with Acute Leukaemia

By Oncology Therapeutic Development (OTD)

Phase I Study: Bromodomain Inhibitor OTX015 in Patients with Acute Leukaemia

By Oncology Therapeutic Development (OTD)
Enter your details to receive the free paper:

Bromodomain and extra-terminal (BET) proteins are chromatin readers that preferentially affect the transcription of genes with super-enhancers, including oncogenes.

BET proteins bind acetylated histone tails via their bromodomain, bringing the elongation complex to the promoter region. OTX015 specifically binds to BRD2, BRD3 and BRD4 to prevent BET proteins from binding to chromatin, inhibiting gene transcription.

OTX015 inhibits proliferation in many haematological malignancy cell lines and patient cells, in vitro and in vivo. OTD Therapeutic Development aimed to establish the recommended dose of OTX-15 in patients with haematological malignancies.

Download this report to find out the results of patients with acute leukaemia, including study methods, findings and interpretation.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology